AU2021102883A4 - Design and evaluation of camel milk as a functional food for anti diabetic property - Google Patents
Design and evaluation of camel milk as a functional food for anti diabetic property Download PDFInfo
- Publication number
- AU2021102883A4 AU2021102883A4 AU2021102883A AU2021102883A AU2021102883A4 AU 2021102883 A4 AU2021102883 A4 AU 2021102883A4 AU 2021102883 A AU2021102883 A AU 2021102883A AU 2021102883 A AU2021102883 A AU 2021102883A AU 2021102883 A4 AU2021102883 A4 AU 2021102883A4
- Authority
- AU
- Australia
- Prior art keywords
- milk
- camel milk
- camel
- insulin
- diabetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 235000020248 camel milk Nutrition 0.000 title claims abstract description 111
- 230000003178 anti-diabetic effect Effects 0.000 title claims abstract description 19
- 238000011156 evaluation Methods 0.000 title claims abstract description 11
- 235000013376 functional food Nutrition 0.000 title claims abstract description 10
- 238000013461 design Methods 0.000 title claims abstract description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 106
- 229940125396 insulin Drugs 0.000 claims abstract description 54
- 108090001061 Insulin Proteins 0.000 claims abstract description 52
- 102000004877 Insulin Human genes 0.000 claims abstract description 52
- 150000001413 amino acids Chemical class 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 12
- 241000282832 Camelidae Species 0.000 claims abstract description 9
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims abstract description 8
- 235000005911 diet Nutrition 0.000 claims abstract description 7
- 238000011161 development Methods 0.000 claims abstract description 5
- 230000028327 secretion Effects 0.000 claims abstract 3
- 235000013336 milk Nutrition 0.000 claims description 26
- 239000008267 milk Substances 0.000 claims description 26
- 210000004080 milk Anatomy 0.000 claims description 26
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 18
- 235000021240 caseins Nutrition 0.000 claims description 18
- 239000005018 casein Substances 0.000 claims description 17
- 235000018102 proteins Nutrition 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 8
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 102000018358 immunoglobulin Human genes 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 229940072221 immunoglobulins Drugs 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 235000021242 lactoferrin Nutrition 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 102000014171 Milk Proteins Human genes 0.000 claims description 3
- 108010011756 Milk Proteins Proteins 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 239000003472 antidiabetic agent Substances 0.000 claims description 3
- 230000000975 bioactive effect Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 3
- 230000002441 reversible effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 108091035707 Consensus sequence Proteins 0.000 claims description 2
- 102400000321 Glucagon Human genes 0.000 claims description 2
- 108060003199 Glucagon Proteins 0.000 claims description 2
- 108010023244 Lactoperoxidase Proteins 0.000 claims description 2
- 102000045576 Lactoperoxidases Human genes 0.000 claims description 2
- 102000016943 Muramidase Human genes 0.000 claims description 2
- 108010014251 Muramidase Proteins 0.000 claims description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 239000000356 contaminant Substances 0.000 claims description 2
- 230000000378 dietary effect Effects 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 229940057428 lactoperoxidase Drugs 0.000 claims description 2
- 229960000274 lysozyme Drugs 0.000 claims description 2
- 235000010335 lysozyme Nutrition 0.000 claims description 2
- 239000004325 lysozyme Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 230000010512 thermal transition Effects 0.000 claims description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 2
- 238000010586 diagram Methods 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 210000002571 pancreatic alpha cell Anatomy 0.000 claims 1
- 230000007065 protein hydrolysis Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 29
- 241000282836 Camelus dromedarius Species 0.000 abstract description 15
- 235000013305 food Nutrition 0.000 abstract description 8
- 239000000047 product Substances 0.000 abstract description 8
- 239000000796 flavoring agent Substances 0.000 abstract description 7
- 235000019634 flavors Nutrition 0.000 abstract description 7
- 150000002632 lipids Chemical class 0.000 abstract description 6
- 241000282414 Homo sapiens Species 0.000 abstract description 5
- 230000037213 diet Effects 0.000 abstract description 5
- 230000035622 drinking Effects 0.000 abstract description 4
- 241000894007 species Species 0.000 abstract description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 239000002105 nanoparticle Substances 0.000 abstract description 3
- 230000017854 proteolysis Effects 0.000 abstract description 3
- 210000002784 stomach Anatomy 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 235000009508 confectionery Nutrition 0.000 abstract description 2
- 235000013365 dairy product Nutrition 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 239000013589 supplement Substances 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 102000011632 Caseins Human genes 0.000 description 19
- 108010076119 Caseins Proteins 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 241000282472 Canis lupus familiaris Species 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 235000020247 cow milk Nutrition 0.000 description 9
- 108010046377 Whey Proteins Proteins 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 235000021119 whey protein Nutrition 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 7
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 5
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 235000008476 powdered milk Nutrition 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 108010063045 Lactoferrin Proteins 0.000 description 2
- 102000010445 Lactoferrin Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 235000020251 goat milk Nutrition 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 229940078795 lactoferrin Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 235000021246 κ-casein Nutrition 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101000976074 Equus caballus Insulin Proteins 0.000 description 1
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 101710114386 Insulin-like protein Proteins 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241001490312 Lithops pseudotruncatella Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 101000993800 Sus scrofa Insulin Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002956 ash Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 108010070004 glucose receptor Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 235000020200 pasteurised milk Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 108010058314 rennet Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003587 threonine derivatives Chemical class 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C1/00—Concentration, evaporation or drying
- A23C1/06—Concentration by freezing out the water
- A23C1/08—Freeze-drying
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/18—Milk in dried and compressed or semi-solid form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/02—Food
- G01N33/04—Dairy products
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/251—Colorimeters; Construction thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/62—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Marine Sciences & Fisheries (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Abstract
DESIGN AND EVALUATION OF CAMEL MILK AS A FUNCTIONAL FOOD FOR
ANTI DIABETIC PROPERTY
Abstract:
Camels have the tendency to yield more food and over longer amounts of time than most certain
species in extreme conditions and low feed demands, indicating their success as dairy products.
Breed, size, equality, season, diet, and management are the most significant factors influencing
camel milk generation. Camel milk is usually translucent and dry, with a sweet and sharp flavour,
but it may also have one salty flavour due to the plants that camels consume in the desert. Camel
milk is well-known among nomads for its ability to treat a variety of diseases, particularly diabetes.
The number of individuals living with type 2 diabetes has increased sharply in recent years,
pushing health-care services beyond their limits. Throughout the Middle East, it is a common
belief that drinking camel milk on a daily basis will help avoid and regulate diabetes. Camel milk
has currently been confirmed to have such features. The following options are suggested from a
study of the literature: 1. Insulin from camel milk has unique features that make it easier to absorb
into the bloodstream than other sourced insulin or induce proteolysis tolerance; 2. Insulin from the
camel is embodied in nanoparticles like lipid vesicles, which enable it to travel via the stomach
and into the circulation; 3. camel milk contains anti-diabetic properties. This invention is intended
in the development and evaluation of functional food from the camel milk for its anti-diabetic
property. The design is capable of finding the amino acid content and correlating it with the human
insulin sequence. This method must be able to formulate and evaluate the anti-diabetic property of
camel milk and will supplement its usage in further development of functional food products from
camel milk which could aid in controlling the diabetics in Human by insulin synthesis and
secretion by the pancreatic p-cells.
1
Description
Description
Field of the Invention:
This invention is intended in the development and evaluation of functional food from the camel milk for its anti-diabetic property. The design is capable of finding the amino acid contents of camel milk and correlating those with the human insulin sequence. This method must be able to find the anti-diabetic property of spray dried and freeze-dried camel milk product.
Background of the Invention:
Camel milk differs from cow milk in molecular structure but it incorporates all essential components and has strong antimicrobial activities due to its high whey proteins, such as immunoglobulin and lactoferrin. Camel milk, in comparison, has more fats and whey protein to cow milk. Camel milk's casein fractions were extracted and determined to be structurally similar to bovine casein. However, the relationship of the two casein fractions is somewhat different, as shown by the low volume of kappa casein, which accounts for just around 5% of overall casein relative to 13.6 percent in bovine casein. The large variation in kappa casein quality can cause issues in cheese production. On the capacity of camel milk to endure enzymatic coagulation, there seems to be little detail. According to reports, a high dose of calf rennet is needed to achieve noticeable coagulation. Camels have the tendency to yield more food and over longer amounts of time than most certain species in extreme conditions and low feed demands, indicating their success as dairy products. Breed, size, equality, season, diet, and management are the most significant factors influencing camel milk generation. During the 8-18-month lactation cycle, individual overall output ranges from 1k to 12k Litres, with significant variations between geographical areas. Camel milk is usually translucent and dry, with a sweet and sharp flavour, but it may also have one salty flavour due to the plants that camels consume in the desert. Camel milk has a significantly lower pH than bovine milk, which is more likely due to elevated levels of vitamin C and some organic acids. Skimmed camel milk has a smaller buffering ability than bovine milk, according to reports.
Agrawal et al. 2011, demonstrated the effect of the camel's milk in diabeticmanagement. During a 52-week controlled trial, the effectiveness of camel milk intake as an alternative to normal diabetic treatment in retaining long-term glycaemia regulation in type I diabetes was evaluated. In every part of the report, 12 patients were randomly assigned to receive regular diabetic management, which included food, insulin and exercise as supplementation, and 12 patients were also randomly chosen to consume pure camel milk on a regular basis. The dosage of parenteral insulin was balanced in each group to sustain a euglycemic condition. At the start ofthe trial, body mass index (BMI) and glycosylated haemoglobin (HbAlc) were measured and followed up with three monthly intervals. At the start and end of the research, plasma insulin, anti-insulin and C-peptide, antibodies were always evaluated. When contrasted to the measurements at the start of the trial, the camel milk community had a substantial increase in mindfulness-based interventions (MBI) and a substantial decrease in HbAlc, mean blood glucose, and required insulin dosage. Anti-insulin, antibodies and c-peptide levels did not improve significantly. We've seen that drinking camel milk reduces the amount of human insulin needed to sustain long-term glycaemic regulationin people with type 1 diabetes. As a consequence of our findings, camel milk intake can be seen as a valuable supplement to parenteral insulin therapy in the treatment of type 1 diabetes. Malik et al., performs literature review to find out whether camel milk alleviates the symptoms of the diabetes. The number of individuals living with type 2 diabetes has increased sharply in recent years, pushing health-care services beyond their limits. Diabetes could affect more than 75% of people living in middle and low salaried countries. Diabetes has the highest prevalence in China and India, with many individuals with diabetes living in severe poverty. The integrated forces of federal health services, foundations, and pharmaceutical company donations would not be enough to meet the financial needs for these people's medications and therapies. As a result, it's worth digging at common folk remedies and see whether there's some experimental evidence to back up their stories of mitigating diabetes symptoms. Throughout the Middle East, it is a common belief that drinking camel milk on a daily basis will help avoid and regulate diabetes. Camel milk has currently been confirmed to have such features. The following options are suggested from a study of the literature: 1. Insulin from camel milk has unique features that make it easier to absorb into the bloodstream than other sourced insulin or induce proteolysis tolerance; 2. Insulin from the camel is embodied in nanoparticles like lipid vesicles, which enable it to travel via the stomach and into the circulation; 3. Camel milk contains anti-diabetic properties. The series of insulin from camel and its expected pattern of digestion do not indicate that it has the capacity to cross mucosal thresholds before being degraded and entering the bloodstream. However, we can't rule out the idea that camel milk contains nanoparticles of the insulin that can carry the enzyme into the bloodstream. Camel milk, on the other hand, is far more likely to produce 'insulin-like' monoclonal antibody compounds that imitate insulin's association with its receptors. Sboui et al., evaluation of pasteurized and raw camel milk. Camel milk is well-known among nomads for its ability to treat a variety of diseases, particularly diabetes. The aim of this research was to see how raw, pasteurised, and boiling camel milk affected Alloxan-induced diabetic dogs. To begin, three classes of dogs were used: group 1 and group 2, each of which consisted of four diabetic dogs who received 250 ml of pure camel milk per dog per day or 250 ml of fresh cow milk per dog per day. The test group consisted of four stable dogs who were fed pure camel milk. Second, we looked at how heat processing affected camel milk's anti-diabetic properties. Two other pairs, each with four diabetes dogs, were given 250 mL of pasteurised camel milk per dog per day or 250 mL of boiling camel milk per dog per day. By the completion of the milk therapy, blood glucose total protein and cholesterol levels had all dropped significantly. Blood glucose, total protein, and cholesterol concentrations were all elevated in animals fed pasteurised camel milk. Every one of these criteria showed no major variations after 3 weeks of diagnosis with pasteurised milk as compared to raw camel milk. The animals given boiled camel milk, on the other hand, had elevated blood glucose, and cholesterol and total proteins levels. This study looked at not just the efficacy of "raw or pasteurised" camel milk in treating diabetic dogs, but also the restorative effect of this substance just after dogs stopped drinking milk. However, when diabetic dogs were treated with distilled camel milk, the medicinal benefit vanished.
Mirmiran et al., experimented with the reduction of the diabetes. Regulating diabetes, a global metabolic condition, with successful alternative drugs is a hot subject right now. Camel milk is thought to be a good hypoglycaemic agent in diabetic patients and laboratory animals. The aim of this systematic study was to see how camel milk affected diabetes. A systematic search was conducted in PubMed and Scopus for all clinical experiments and animal studies focusing on the impact of camel milk on diabetes markers that were published up to 2015. There were studies that looked at the impact of camel milk on parameters of glucose and lipid profiles in humans with diabetes, with no dosage restriction. There were 73 papers included in the first quest. After reviewing abstracts and complete texts, 22 papers were selected, including 11 animal experiments and 11 clinical studies, with eight focusing on type 1 diabetes and three on type 2 diabetes. With the exception of one, all animal experiments reported substantial declines in at least one of the diabetes metrics. The prescribed dosage of camel milk in many other clinical trials was 500 m/day, which resulted in improvements in diabetes indicators in patients with diabetes only after three months. The majority of the findings used in this systematic analysis showed that camel milk has beneficial consequences on diabetes mellitus, such as lowering blood sugar, declining insulin tolerance, and enhancing lipid profiles.
Objective of the Invention:
1. To determine the percentage content of the amino acids in the major proteins present in female camel milk and correlate that with sequence of human insulin. 2. To determine and characterize the functional properties of female camel milk proteins isolates in relation with their molecular structural changes and to study the thermal transition characteristics and anti-diabetic property. 3. To produce functional foods as spray dried and freeze-dried camel milk product and in vivo evaluation of the anti-diabetic property.
Summary of the Invention:
Milk is consumed regularly by large numbers of people all over the world because of its many health advantages, including the development and advancement of bones in small children since milk is a healthy vitamin D and calcium source. It is helpful to the elderly, particularly in menopausal women, whereby calcium deficiency is a major trigger for osteoporosis. Milk is a protein source as well as a means of food protection and revenue for the majority of people in the developed world. Milk processing is carried out by about 145 billion families around the world. Due to the extremely rapid cash flow, it is especially beneficial to small-scale farmers. Camel's milk contains all of the nutrients that humans need than any other milk.
Furthermore, it has medicinal properties. Camel's milk is pure white with a mildly salty flavour and a pH level of 6.2 to 6.5, which is smaller than cow's milk. This has a negative impact on health, with 96% triglycerides and maximum dry cholesterol of 30 mg/100 g. The fat contains fewer simple fatty acids than cow's milk. Moreover, as applied to fatty acids from goat milk, fat globules, bovine, and the buffalo are lower on a median. Camels'milk is easily digestible, which may create issues in technical applications. Camel milk is rich in vitamins B1, B2, and C and vitamin C content is 3-5 times that of cow's milk, making it a vital part of the diet in arid regions in which healthy foods are scarce.
Camels' milk is already found to have bactericidal, anti-diabetic, and anti-hepatitis properties. Lacto-peroxidase structure, immunoglobulins, lysozyme, lactoferrins, and free greasy acids are all potential inhibitory mechanisms that help it avoid microbial infection to varying degrees. Freezing and dry spray are two techniques for turning milk into powder. The physicochemical properties of dried milk are affected by each process. Lyophilization is a process that involves freezing small quantities of a substance and then placing it under a vacuum. The liquid condenses are frozen in a vacuum, whereas the ice transforms into vapor independent of defrosting. After that, the water is gradually separated from the liquid until it reaches the center. Besides heat-sensitive materials, the lyophilization methodology is regarded as an outstanding drying method.
Despite the benefits, it's worth noting that the procedure is thought to be the most expensive way to make dehydrated food. The product's composition is preserved, and the dry material absorbs easily during the process. Owing to the vacuum, the snow can quickly evaporate before melting back into the water, ensuring that the majority of the flavour, surface, and nutrients can stay intact. In comparison with products drying using traditional methods, reasonable processing parameters allow us to achieve the highest quality products. Dry spray is a popular drying process since it requires very little heat time available and an increased evaporation rate to generate a significant product at the lowest possible cost.
Camel milk is investigated in a meta-analysis report, with the following details: Camel milk contains a mean of 3.1% protein, 3.5% sugar, 4.3% lactose, 0.73% ashes, and 11.9% total solids. Water quality is the most significant component in camel milk. The average solid content of this product is comparable with that of human milk. The overall protein present in camel milk is stated to ranging in between 2.9-4.9. Whey proteins and caseins are the two types of proteins found in camel milk.
The proteins are key elements of camel milk and serve a variety of purposes. Exception of glycine, threonine, valine, and lysine camel milk has a wide volume and variety of amino acids. Whey proteins include lactoferrin, albumin, immunoglobulins, and proteins are the most essential proteins in camel milk. Dromedary camel milk has a fat value of 1.2%-6.4%. Camel milk has a poor concentration ofunsaturated fatty acids than saturated fatty acids. Linoleic acid is one of the unsaturated fatty acids present in high amount in camel milk and which is good for our health. The overall value of lactose in camel milk is being recorded. Camel milk is high in fat-soluble and water-soluble nutrients, including vitamin A, E, D, and B. Camel milk is high in minerals, calcium, potassium, iron, copper, magnesium and kalium.
Insulin is an essential hormone that sends signals to the brain about how much glucose is present in the blood at any given time. The glucose levels in the blood are elevated; insulin is produced in the pancreas then released into the bloodstream. The signal travels to the muscles, liver, and fat cells within the body. Insulin instructs the organs to remove glucose from the bloodstream further store it as fat or glycogen. The body contains relatively limited glycogen; the glycogen contained in the muscle and liver will be insufficient to keep yourself sufficiently for an active day. Sugar is processed as saturated fat until the glycogen reserves are depleted. Insulin regulates sugar homeostasis by promoting glucose absorption in muscle contraction to a lower degree, adipose tissue, and liver. The phosphorylation of serine or threonine compounds appears to influence key enzymes in regulating the glucose metabolism insulin. Glucose receptor reacting to binding site activates all insulin recognized activities at the plasma membrane. Standard, bioactive insulin is monomeric acts as a single compound and it has 2 polypeptide chains that are amino acids with long chains. Chain A contains 21 amino acids whereas chain B contains amino acids. The chains are covalently linked by two disulfide bonds (residues A7 to B7 while A20 to B19), and chain A comprises an intrinsic disulfide bridge from A6 to Al1. Both mammal sources of insulin have identical joints. Insulin is released into two form dimmers, and in six forms of hexamers, and these are considered in the zinc presence.
Detailed Description of the Invention: Camel milk has a relatively higher protein content (2.1 to 5.6%) than cow milk. The casein concentration of Bactrian and dromedary milk and the albumin composition are ranging from 2.7% - 0.88% and 3.8% - 0.96%. The protein content is ranging between 3.5% - 3.8%, while casein content is ranging between 2.7% - 2.8%. The Egyptian camels contain a casein content of 2.5%. In contrast to cow milk, camel milk's casein percentages are observed to be lower in protein content. Industrial camel milk casein has an amino acid structure and an increased protein content that suggests it may be a good dietary substitute for humans. Moreover, the disgusting odour and flavour render it unfit for human and animal feeding. It is assumed that camel industrialized casein could be purified and thereby made suitable for human use. The milk's protein content from a dehydrated camel is very low. This shows that water supply has a significant influence on the formation of milk. It is important to note that the nutritional value of the diet has a significant impact on the milk's protein content. In Bactrian milk, there is a reduction in amino acid content lactation progresses. The nutritional content namely, phenylalanine, valine, leucine, methionine, and arginine levels are higher in goat milk in comparison with cow milk. Camel milk has a nitrogen value of 15.5 grams per 100 grams. The preceding amino acids are included in sample: proline 13.3; threonine 6.9; valine 7.4; alanine 3.05; asparagine 7.65; glutamine 23.4; isoleucine 6.4; lysine 7.6; methionine 3.5; serine 5.7; arginine 3.13; asparagine 7.63; leucine 10.2; histidine 2.4; glycine 1.55; tyrosine 5.8; ammonia 1.72; methionine 3.3 phenylalanine 5.3. The cold casein collections contain acid hydrolysis is conducted as per the AOAC process, followed by amino acid evaluation using converse phase highly pressurized chromatography.
Shimpack amino-Na form section (11 cm•7.0 mm) is being used to test the items. The amino acids in the datasets are functionalized with O-phthadialdehyde (OPA), which has been identified utilizing the fluorescent detection method, and the results are combined with an integrator. The Kjeldahl method is being used to evaluate nitrogen content. The protein concentration in raw milk and different extracts is calculated using nitrogen correction factors of 6.37. Casein N, complete nitrogen (TN), whey protein nitrogen (WPN), and NPN proportions are measured. Whey proteins contain distinct properties. They include geological, biological, biochemical, functional, and technical properties that may be suitable for food products, in addition to their nutritional importance. Whey proteins are nutritionally important as they have calories and significant amino acids, as well as functionally important because they aid in shape, shape alteration, and total food presentation, such as foam consistency, gel-forming, and water retention. The bromelain, proteolytic enzymes alcalase, and papain are often used in an analysis to make camel's milk protein hydrolyzed. Emulsifying field of activity, protein solubility, and surface hydrophobicity are examined as technological characteristics function. Diabetes impacts a large number of people throughout the world. It's a long-term disorder in which an organism can't generate sufficient insulin, can't use the insulin it does generate, or can't do both. The utilization of camel's milk through type diabetes patients has been shown to reduce blood glucose levels in clinical testing and murine approaches. Camels' milk tended to provide protein insulin that opposes intestinal digestions, consumes quicker into blood, includes wider lipid micelles, and also has a distinct casein quality via the cause is unknown. The human digestive system has poor coagulation of camel's milk as well as the impact of immunoglobulins camel's milk has a limited b-cells size, and contributed to the potential hypoglycaemic influence. A potentiating impact of insulin receptor activation's camel milk displayed in HEK293 cells is identified via in vitro analysis that could be a potential mode of action. Hydrolysates and whey proteins can resolve glycaemia by triggering the release of gut hormones via producing amino acids and bioactive peptides in vivo. In addition, in vivo, the peptides might suppress dipeptidyl peptidase-4 (DPP-IV). As DPP-IV inhibition seems to have become effective in the treatment of type 2 diabetes, DPP-IV multiple inhibition peptides are being extracted and characterized via caprine casein and bovine. The majorities of DPP-IV inhibition peptides include hydrophobic amino acids but have molecular weight under 2 kDa. Insulin patterns are derived from a variety of species. PSI-BLAST utilized the insulin of camel as a basis for the series. Sequence analysis is being used to match sequence homology insulin from living things. The conservation group of the Numerous Sequence Analysis is custom made. BLOSUM62 acquired from MAFFT Numerous Sequence Analysis is also used to build a phylogenetic tree with amino acid insulin composition. BLOSUM62 is used to determine the coordination consistency of amino acid composition.
Barton and living stone are used to quantify the preservation of insulin components. Consensus sequences describe the most frequent contaminants at a given location after several sequence analyses. The reverse probability of unfavourable mutations in several coordinated insulin components is measured by quality performance. Camel insulin varies into four mutations obtained from human insulin but still, buffalo and bovine insulin produce single mutations. Neither of the mutations impairs digestive enzyme precision. In aspects of proteolysis resistance, camel insulin ought to be similar to bovine, human, sheep, buffalo, horse, and pig insulin. The camel insulin ought to be digested as all secured mammal insulin whenever it interacts with the digestive system's proteases. Camel milk doesn't readily coagulate at lower concentrations, has a high buffering ability, differs in fatty acid and casein concentrations, and produces greater lipid micelles unlike milk from other species. It's probable the insulin of camel milk is embodied in micelles but flows to the intestine via the stomach.
The two spray dry runs contain powders 1 and 2 of camel milk are contrasted. The procedure specifics indicate every run, like camel milk powder 1 is extracted through the milk concentrate spray as very small droplets into a warm dry air stream from a nozzle, in which the milk concentration is synchronized with the path of warm air, but camel milk powder 2 is extracted by a drying process. The temperature remains stable at 208°C, the amount of water movement is lower while the direction of feeding is co-current (hot dry air direction) in comparison with the feeding direction in reverse current, and while the interaction of dry hot air along with feed is greater. Color concentration is evaluated for every run, and the outcomes of the colorimetric analyses are listed, that described the yellowness and lightness phenomena of 48 milk powders and their interaction, so that camel powdered milk 1 has a greater premium of 94.37 "L", but the quite reduced value of "b" than camel powdered milk 2, specifying the co-relation among yellowness and lightness of 48 milk powders. Solubility is a crucial factor to consider when evaluating the physical properties of milk powder.
The tendency of desiccated milk to shape a suspension, solution, or emulsification when combined with liquids that would mimic the physical features of natural milk is calculated as an in-solubility scale. Two very different powders 1 and 2 has in-solubility indices above the specified limits of 0.3 ml, though camel powdered milk 1 has a marginally reduced in-solubility value in comparison with camel powdered milk 2 leading to a smaller proportion of moisture levels, caused by increased interaction among the hot dry air and the feed.
A maximum of 24 patients with type 1 diabetes are enrolled at variance and offered their written permission prior to participating in the research. With one month, the patients are instructed to adhere to a rigid diet, workout, and insulin therapy regimen. At that time, blood sugar levels were closely monitored in order to sustain euglycemia. The patients are randomly split into two categories after one month. Patients in trial 1 required standard treatment, such as food, workout, and insulin, while patients in trail 2 obtained 500ml of natural camel milk every day for one year in contrast to regular care.
Insulin drops are determined by titration regularly based on blood glucose levels, which are calculated twice between breakfast and dinner. An exclusive image memory glucometer Scan is presented to each patient, together with a strip to analyze blood glucose levels. The diaries of their sugar levels and insulin concentrations are maintained. Pulse rate, haematologic, weight, and lab measurements, and glycosylated haemoglobin (HbA lc) are all kept track. Patients often kept track of hypoglycemia signs and, if appropriate, received blood glucose as they appeared. At the start and conclusion of this research, anti-insulin antibodies are assessed. Vital signs and lab parameters are used in the safety assessments. Extreme hypoglycemia is characterized as an occurrence that necessitated the support of some other person or the management of intravenous glucose or glucagon is described as an incidence rate every patient-year access, allowing for numerous instances in the respective patients as well as discrepancies in research drug exposure period. Camel milk contains approximately 52 microunits/ml insulin, which enables a better understanding of diabetic patients who drink camel milk need low insulin. After intake of camel milk for about 8 months, a patient no longer needed insulin treatment. Camel milk's loss of coagulum can function as an important medium for transporting intact milk insulin into the intestine, where it is ingested even though most of it is damaged in the path. The outcomes of this analysis show that camel milk has a significant hypoglycaemic effect once used as a treatment modality, owing to the existence of the insulin-like protein. The deficiency of coagulum production in camel milk in an adverse setting can explain its therapeutic potential. Oral insulin does not inhibit the loss of beta-cell activity in patients with type 1 diabetes. Camel milk tends to be stable and effective in enhancing long-term glycemic regulation and lowering insulin requirements in patients with type 1 diabetes when used in conjunction with insulin treatment. Camel milk is very well handled, and it is not linked to an increased risk of hypoglycaemia.
Claims (3)
1. To determine the percentage content of the amino acids in the major proteins present in female camel milk and correlate that with sequence of human insulin. i. From claim 1, the proteins are key elements of camel milk and serve a variety of purposes. Exception of glycine, threonine, valine, and lysine camel milk has a wide volume and variety of amino acids. Industrial camel milk casein has an amino acid structure and an increased protein content that suggests it may be a good dietary substitute for humans. ii. From claim 1, standard, bioactive insulin is monomeric acts as a single compound and it has 2 polypeptide chains that are amino acids with long chains. Chain A contains 21 amino acids whereas chain B contains 30 amino acids.
2. To determine and characterize the functional properties of female camel milk proteins isolates in relation with their molecular structural changes and to study the thermal transition characteristics and anti-diabetic property. i. From claim 2, camels' milk is already found to have bactericidal, anti-diabetic, and anti-hepatitis properties. Lacto-peroxidase structure, immunoglobulins, lysozyme, lactoferrins, and free greasy acids are all inhibition mechanisms that help it avoid micro-organism infection to varying degrees. ii. From claim 2, consensus sequences describe the most frequent contaminants at a given location after several sequence analyses. The reverse probability of unfavorable mutations in several coordinated human insulin components is measured by quality performance.
3. To formulate and evaluate the anti-diabetic property of functional food products developed as spray dried and freeze-dried camel milk. i. From claim 3, lyophilization is a process that involves freezing small quantities of a substance and then placing it under a vacuum. ii. From claim 3, dry spray is a popular drying process since it requires very little heat time available and an increased evaporation rate to generate a significant product at the lowest possible cost.
DESIGN AND EVALUATION OF CAMEL MILK AS A FUNCTIONAL FOOD FOR 27 May 2021
ANTI DIABETIC PROPERTY
Diagram
Ala.Lys.Pro.Thr.Tyr.Phe.Phe.Gly. Arg 2021102883
. NH2 NH2 Glu | | . Phe.Val.Asp.Glu.His.Leu.Cys.Gly.Ser.His.Leu.Val.Glu.Ala.Leu.Tyr.Leu.Val.Cys.Gly | \ S S | \ NH2 S NH2 NH2 S NH2 | | | | \ | Gly.Ile.Val.Glu.Glu.Cys.Cys.Ala.Ser.Val.Cys.Ser.Leu.Tyr.G lu.Leu.Glu.Asp.Tyr.Cys.Asp
S S
Figure 1: Structure of the normal Insulin.
Figure 2: Camel’s milk and its importance.
Stimulating Glucose- mediated insulin secretion
Inhibiting the secretion of Camel Milk Glucagon Protein pancreatic α-cells and its function in liver 2021102883
Restore and increase Human Insulin Inhibiting the key enzymes that directly control the secretion of insulin
dipeptidyl peptidase IV (DPP-IV)
Figure 3: The anti-diabetic mechanism and protein hydrolysis of the camel’s milk.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021102883A AU2021102883A4 (en) | 2021-05-27 | 2021-05-27 | Design and evaluation of camel milk as a functional food for anti diabetic property |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021102883A AU2021102883A4 (en) | 2021-05-27 | 2021-05-27 | Design and evaluation of camel milk as a functional food for anti diabetic property |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2021102883A4 true AU2021102883A4 (en) | 2021-07-29 |
Family
ID=76972067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2021102883A Ceased AU2021102883A4 (en) | 2021-05-27 | 2021-05-27 | Design and evaluation of camel milk as a functional food for anti diabetic property |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2021102883A4 (en) |
-
2021
- 2021-05-27 AU AU2021102883A patent/AU2021102883A4/en not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nongonierma et al. | The scientific evidence for the role of milk protein-derived bioactive peptides in humans: A Review | |
JP5728512B2 (en) | Composition containing dipeptide as active ingredient | |
Calbet et al. | Plasma glucagon and insulin responses depend on the rate of appearance of amino acids after ingestion of different protein solutions in humans | |
US20190105371A1 (en) | Uses of casein compositions | |
CN106983854A (en) | For PKU and the PROVON 190 medicinal food of the nutritional control of other metabolic diseases | |
Manninen | Hyperinsulinaemia, hyperaminoacidaemia and post-exercise muscle anabolism: the search for the optimal recovery drink | |
JP6227519B2 (en) | Leucine-rich peptide composition and isolation method | |
Pihlanto | Whey proteins and peptides: Emerging properties to promote health | |
CN105451578A (en) | Chromatographic separation of sugars using blend of cation exchange resins | |
Wang et al. | Natural bioactive peptides to beat exercise-induced fatigue: A review | |
Uneyama et al. | New functions and potential applications of amino acids | |
Sumaira et al. | Composition and beneficial impact of camel milk on human health | |
EP1358878A1 (en) | Remedies/preventives for inflammatory diseases | |
JP5841556B2 (en) | Composition of whey growth factor extract for reducing muscle inflammation | |
AU2021102883A4 (en) | Design and evaluation of camel milk as a functional food for anti diabetic property | |
RU2713935C1 (en) | Peptides of marine origin and fish nucleotides, compositions and use thereof for reducing blood glucose | |
US20060204549A1 (en) | Method of improving nutrient utilisation by a mammal and a composition for use therein | |
Gupta et al. | Whey proteins and its impact on human health nutrition: review | |
Park et al. | Low-molecular collagen peptide supplementation and body fat mass in adults aged≥ 50 years: a randomized, double-blind, placebo-controlled trial | |
Kumari et al. | Influence of dietary molecules on human health: Whey proteins | |
Shelestun et al. | Serum–what is this product and to whom it is useful | |
CN115666617A (en) | Insulinotropic and glucagon stimulating action of beta-lactoglobulin | |
CN112135531A (en) | Insulin control in overweight or obese adults during lifetime intervention | |
Shi | Metabolic effects of whey proteins in an experimental model of diet-induced obesity | |
Rankin | Effect of various whey protein supplements on recovery from prolonged endurance exercise in trained cyclists: a thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Nutritional Science at Massey University, Palmerston North, New Zealand |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGI | Letters patent sealed or granted (innovation patent) | ||
MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |